Brief: Herantis Pharma: CDNF Phase I-II Study Met Primary Endpoints

Herantis Pharma Oyj

27/08/2020 07:18

Aug 27 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA PLC ANNOUNCES CDNF PHASE I-II STUDY MET PRIMARY ENDPOINTS OF SAFETY AND
TOLERABILITY AT 12 MONTHS
    * NOVEL DRUG CANDIDATE, CEREBRAL DOPAMINE NEUROTROPHIC FACTOR (CDNF) FOR TREATMENT OF
PARKINSON'S
DISEASE (PD), HAS SUCCESSFULLY ACHIEVED ITS PRIMARY ENDPOINT
    * ANALYSES OF IMPORTANT ADDITIONAL EXPLORATORY OUTCOME MEASURES, SUCH AS CEREBROSPINAL FLUID
ALPHA-SYNUCLEIN AND PROTEOMICS STUDIES, ARE ONGOING AND EXPECTED TO BE COMPLETED IN Q4 2020
    * FURTHER DEVELOPMENT OF CDNF BY HERANTIS INCLUDES POTENTIAL FOLLOW ON CLINICAL STUDIES AND
ADDITIONAL OPTIMIZATION OF DOSING, DELIVERY AND PATIENT SELECTION

Source text for Eikon:  ID:nWkrgDnqh 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))